Please assess the completion status of the following clinical trial:

Trial Title: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed mycosis fungoides or Sezary syndrome~  * Stage IB-IVB disease~ * Must have failed at least one prior systemic therapy~ * Generalized erythroderma allowed~* Measurable disease and at least one indicator lesion OR evaluable disease for erythrodermic patients only~  * Prior radiotherapy to areas of measurable disease allowed if disease progression is present in the site or if measurable disease is present outside irradiation port~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2 OR~* WHO 0-2~Life expectancy:~* At least 3 months~Hematopoietic:~* WBC at least 3,000/mm\^3~* Absolute granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.2 mg/dL~* SGOT or SGPT no greater than 2 times upper limit of normal (ULN)~* Alkaline phosphatase no greater than 2 times ULN~Renal:~* Creatinine no greater than 2.0 mg/dL~Cardiovascular:~* No New York Heart Association class III or IV heart disease~* No clinically significant peripheral venous insufficiency~Other:~* HIV negative~* No poorly controlled diabetes mellitus~* No acute infection requiring IV antibiotics~* No other medical condition that would prevent ingestion or absorption of oral medication~* No other neoplasm within the past 5 years except curatively treated squamous cell or basal cell skin cancer, melanoma in situ, or carcinoma in situ of the cervix~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior biologic therapy and recovered~* No concurrent growth factors or epoetin alfa~Chemotherapy:~* At least 4 weeks since prior chemotherapy and recovered~Endocrine therapy:~* At least 4 weeks since prior topical steroids~Radiotherapy:~* See Disease Characteristics~* At least 2 weeks since prior radiotherapy for local control or palliation and recovered~Surgery:~* Recovered from prior major surgery~Other:~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).